I rise today to voice my great concern about FDA's recent announced cutbacks in its cosmetic regulatory program. I wanted to bring to your attention a matter concerning the funding of the Food and Drug Administration's (FDA) regulatory program for cosmetics. While I am mindful of how difficult appropriations allocation decisions are given the discretionary budgetary caps we enacted last year, I know that you have consistently worked over the years to see that the FDA would have adequate funding for its vital consumer protection mission. It has come to my attention that FDA has recently informed the cosmetic industry of its intent to decrease substantially both the personnel and financial resources devoted toward its cosmetics regulatory program.
Orrin Hatch: “I rise today to voice my great concern about FDA's recent announced cutbacks in its cosmetic regulatory program. I…”
Editor's note · Context
Addressing concerns about FDA cutbacks in its cosmetic regulatory program.
Share
More from Orrin Hatch
I stand by everything I said during my questioning of Mr. Saul, including concerns about budget summary data.
The Finance Committee has worked with the Treasury Department to ensure proper responsiveness to committee inquiries. We are continuing to review these matters to determine what further oversight is required.
It is disappointing the ranking member feels a need to question a statement that I made during the hearing.
I want to thank my dear colleague from Iowa. He is one of the greatest Senators I have served with. He is just a wonderful friend and a wonderful Senator. He has worked his tail off the whole time he has been here. I am grateful for his…





